Urine TB LAM as a Tool for Helping Diagnosis and Follow Up of Treatment Response of Pulmonary Tuberculosis
Article Sidebar
Main Article Content
Abstract
OBJECTIVES: To evaluate role of urine Tuberculosis Lipoarabinomannam (TB LAM) in making a diagnosis among human immunodeficiency virus (HIV) negative patients with pulmonary tuberculosis.
MATERIALS AND METHODS: Sixty-six cases of HIV negative who were suspected of pulmonary tuberculosis were recruited, sputum examination of acid fast stain and culture, chest x-ray, urine TB LAM were sent, bronchoscopy and washing and biopsy were performed among 12 cases.
RESULTS: Thirty-six patients were finally diagnosed as tuberculosis. The sensitivity of urine TB LAM was 66.7%, specificity was 90%.
CONCLUSION: TB LAM should be used as an add-on to clinical judgement in combination with other tests. Keywords: urine TB LAM, pulmonary tuberculosis
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This article is published under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). You may copy and redistribute the material for noncommercial purposes, provided that appropriate credit is given and a link to the license is included. Modified versions may not be distributed under this license.
License: https://creativecommons.org/licenses/by-nc-nd/4.0/
References
World Health Organization (WHO). WHO updates policy for the use of lateral flow urine lipoarabinomannan assay (LF-LAM) for diagnosing active tuberculosis in people living with HIV. at 4/11/2019. (Accessed at January 15, 2023 at https://www.who.int/news/item/04-11-2019-who-updates policy-for-the-use-of-lateral-flow-urine-lipoarabinomannan assay-(lf-lam))
Huerga H, Bastard M, Lubega AV, et al. Novel FujiLAM assay to detect tuberculosis in HIV positive patients in four African countries: a diagnostic accuracy study. Lancet Glob Health 2023;11(1):e126-e135. doi: 10.1016/S2214- 109X(22)00463-6.
World Health Organization (WHO). Global tuberculosis report 2020;1-232 . (Accessed at January 15, 2023 at https://www. who.int/publications/i/item/9789240013131).
Bulterys MA, Wagner B, Redard-Jacot M, et al. Point-of-Care urine LAM tests for tuberculosis diagnosis: A status update. J Clin Med 2019;9(1):111. doi: 10.3390/jcm9010111.
Kawasaki M, Echiverri C, Raymond L, et al. Lipoarabinoman nan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts. PLoS Med 2019;16(4):e1002780. doi: 10.1371/journal.pmed.1002780.
Suwanpimolkul G, Kawkitinarong K, Manosuthi W, et al. Utility of urine lipoarabinomannan (LAM) in diagnosing tuberculosis and predicting mortality with and without HIV: prospective TB cohort from the Thailand Big City TB Research Network. Int J Infect Dis 2017;59:96-102. doi: 10.1016/j.ijid.2017.04.017.
Amin AG, De P, Graham B, et al. Urine lipoarabinomanan in HIV uninfected, smear negative, symptomatic TB patients: effective sample pretreatment for a sensitive immunoassay and mass spectrometry. Sci Rep 2021;11(1):2922. doi: 10.1038/s41598-021-82445-4
